GALCANEZUMAB
Information current as at: 1 April 2025
No activity by the pharmaceutical company has been recorded for this medicine for six(6) months. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Emgality®
- Pharmaceutical company:
- Eli Lilly Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic migraine
- PBAC Submission type:
- New listing (Major)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2019
- Related medicines:
Progress Details
-
Submission received for: - July 2019 PBAC meeting
-
Opportunity for consumer comment: - Open 01/05/2019 and close 12/06/2019 (see PBS Website)
-
PBAC meeting: - Held on 10/07/2019
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a021
Page last updated: 31 October 2024